Cargando…

Genomic profiling and immune landscape of olfactory neuroblastoma in China

BACKGROUND: Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of the olfactory mucosa. The paucity of genomic data has prevented the development of individualized ONB treatments. Here, we investigated the genomic and immune landscape of ONB in Chinese patients. METHODS: Whole exome sequenci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yunyun, Wan, Zhiyi, Zhang, Enli, Piao, Yingshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646513/
https://www.ncbi.nlm.nih.gov/pubmed/38023213
http://dx.doi.org/10.3389/fonc.2023.1226494
_version_ 1785134911559041024
author Yang, Yunyun
Wan, Zhiyi
Zhang, Enli
Piao, Yingshi
author_facet Yang, Yunyun
Wan, Zhiyi
Zhang, Enli
Piao, Yingshi
author_sort Yang, Yunyun
collection PubMed
description BACKGROUND: Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of the olfactory mucosa. The paucity of genomic data has prevented the development of individualized ONB treatments. Here, we investigated the genomic and immune landscape of ONB in Chinese patients. METHODS: Whole exome sequencing (WES) and multiplex immunofluorescence (MIF) analysis were performed on tissue samples from 19 Chinese ONB patients. Patients were divided into low- and high-grade groups. RESULTS: Overall, 929 nonsynonymous alterations were identified in 18 (94.74%) ONB cases. The most prevalent altered cancer-related genes were CTNNB1 (16%) and ZNRF3 (16%). The most mutated oncogenic pathways were the WNT and RAS pathways. The median tumor mutation burden (TMB) was 0.45, ranging from 0 to 3.25. Only one case expressed PD-L1 (> 1%) in the tumor region. The percentage of CD8+ tumor-infiltrating lymphocytes (TILs) in the tumor region ranged from 0.03% to 84.9%, with a median of 1.08%. No significant differences were observed between the low- and high-grade groups for clinicopathological features, mutant genes, mutant pathways, TMB, tumor neoantigen burden (TNB), mutant-allele tumor heterogeneity (MATH), PD-L1 expression levels, or CD8+ TIL percentage. However, the low-grade group showed significantly more CD68+ macrophages in both the tumor and total region than the high-grade group. Notably, CD68+CD163- macrophages accounted for an average of 80.5% of CD68+ macrophages. CONCLUSION: This study presents data on the genomic and immune landscape of ONB cases in China. CTNNB1 and ZNRF3 were the most prevalent altered cancer-related genes. The results of TMB, PD-L1, and CD8+ Tils suggest that ONB may be insensitive to immunotherapy. M1 macrophages may be positively associated with the prognosis of ONB. IMPLICATIONS FOR PRACTICE: In this study, the most prevalent altered cancer-related genes were CTNNB1 (16%) and ZNRF3 (16%). The most mutated oncogenic pathways were the WNT and RAS pathways. The median tumor mutation burden (TMB) was 0.45, ranging from 0 to 3.25. Only one (1/15) case expressed PD-L1 (> 1%) in the tumor region. However, the low-grade group showed significantly more CD68+ macrophages in both the tumor and total region than the high-grade group. The higher level of CD68-related macrophages indicates that M1 macrophages potentially play an important role in ONB development that is possibly associated with prognosis.
format Online
Article
Text
id pubmed-10646513
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106465132023-01-01 Genomic profiling and immune landscape of olfactory neuroblastoma in China Yang, Yunyun Wan, Zhiyi Zhang, Enli Piao, Yingshi Front Oncol Oncology BACKGROUND: Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of the olfactory mucosa. The paucity of genomic data has prevented the development of individualized ONB treatments. Here, we investigated the genomic and immune landscape of ONB in Chinese patients. METHODS: Whole exome sequencing (WES) and multiplex immunofluorescence (MIF) analysis were performed on tissue samples from 19 Chinese ONB patients. Patients were divided into low- and high-grade groups. RESULTS: Overall, 929 nonsynonymous alterations were identified in 18 (94.74%) ONB cases. The most prevalent altered cancer-related genes were CTNNB1 (16%) and ZNRF3 (16%). The most mutated oncogenic pathways were the WNT and RAS pathways. The median tumor mutation burden (TMB) was 0.45, ranging from 0 to 3.25. Only one case expressed PD-L1 (> 1%) in the tumor region. The percentage of CD8+ tumor-infiltrating lymphocytes (TILs) in the tumor region ranged from 0.03% to 84.9%, with a median of 1.08%. No significant differences were observed between the low- and high-grade groups for clinicopathological features, mutant genes, mutant pathways, TMB, tumor neoantigen burden (TNB), mutant-allele tumor heterogeneity (MATH), PD-L1 expression levels, or CD8+ TIL percentage. However, the low-grade group showed significantly more CD68+ macrophages in both the tumor and total region than the high-grade group. Notably, CD68+CD163- macrophages accounted for an average of 80.5% of CD68+ macrophages. CONCLUSION: This study presents data on the genomic and immune landscape of ONB cases in China. CTNNB1 and ZNRF3 were the most prevalent altered cancer-related genes. The results of TMB, PD-L1, and CD8+ Tils suggest that ONB may be insensitive to immunotherapy. M1 macrophages may be positively associated with the prognosis of ONB. IMPLICATIONS FOR PRACTICE: In this study, the most prevalent altered cancer-related genes were CTNNB1 (16%) and ZNRF3 (16%). The most mutated oncogenic pathways were the WNT and RAS pathways. The median tumor mutation burden (TMB) was 0.45, ranging from 0 to 3.25. Only one (1/15) case expressed PD-L1 (> 1%) in the tumor region. However, the low-grade group showed significantly more CD68+ macrophages in both the tumor and total region than the high-grade group. The higher level of CD68-related macrophages indicates that M1 macrophages potentially play an important role in ONB development that is possibly associated with prognosis. Frontiers Media S.A. 2023-11-01 /pmc/articles/PMC10646513/ /pubmed/38023213 http://dx.doi.org/10.3389/fonc.2023.1226494 Text en Copyright © 2023 Yang, Wan, Zhang and Piao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Yunyun
Wan, Zhiyi
Zhang, Enli
Piao, Yingshi
Genomic profiling and immune landscape of olfactory neuroblastoma in China
title Genomic profiling and immune landscape of olfactory neuroblastoma in China
title_full Genomic profiling and immune landscape of olfactory neuroblastoma in China
title_fullStr Genomic profiling and immune landscape of olfactory neuroblastoma in China
title_full_unstemmed Genomic profiling and immune landscape of olfactory neuroblastoma in China
title_short Genomic profiling and immune landscape of olfactory neuroblastoma in China
title_sort genomic profiling and immune landscape of olfactory neuroblastoma in china
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646513/
https://www.ncbi.nlm.nih.gov/pubmed/38023213
http://dx.doi.org/10.3389/fonc.2023.1226494
work_keys_str_mv AT yangyunyun genomicprofilingandimmunelandscapeofolfactoryneuroblastomainchina
AT wanzhiyi genomicprofilingandimmunelandscapeofolfactoryneuroblastomainchina
AT zhangenli genomicprofilingandimmunelandscapeofolfactoryneuroblastomainchina
AT piaoyingshi genomicprofilingandimmunelandscapeofolfactoryneuroblastomainchina